Call Us: (1) 608 441-2729 - Email Us firstname.lastname@example.org
M2SR: The Vaccine
Board of Directors
Clinical Advisory Board
News and opinions
Isthmus Article: A Better Flu Vaccine. FluGen strives to make it more effective, plus pain-free
November 6, 2012
Share this Story
Comments are closed.
FluGen to Present at Baird’s 2021 Global Healthcare Conference
FluGen Announces Publication of Positive Results from Phase 2 Human Challenge Study of Its M2SR Vaccine Candidate Against Highly Drifted Strain of H3N2 Influenza Virus
FluGen Awarded US Department of Defense Funding to Conduct Clinical Study Evaluating Investigational M2SR Flu Vaccine and Current Standard-of-Care High Dose Vaccine
Watch FluGen President & CEO Paul Radspinner speak at the Jefferies 2021 Virtual Healthcare Conference
FluGen Initiates NIH-Funded Trial of M2SR Flu Vaccine; First Study in Adults Up to Age 85
(c)2016 FluGen, Inc. All rights reserved.
Back to Top